Immunotherapy for malignant mesothelioma: reality check

Area of Science:

• Oncology
• Immunology
• Cancer Treatment

Background:

• Malignant mesothelioma (MM) treatment has seen initial promise with immune-based therapies.
• However, treatment outcomes have been inconsistent, and recent studies on immune checkpoint inhibitors have reduced optimism.

Purpose of the Study:

• To comprehensively discuss the basis, modalities, and updated results of immunotherapy in MM.
• To evaluate the potential of immunotherapy in improving malignant mesothelioma treatment outcomes.

Main Methods:

• A comprehensive literature search was conducted for relevant studies and meeting abstracts.
• The review focused on the principles, methods, and recent findings of immunotherapy in MM.

Main Results:

• Initial studies demonstrated that modulating the immune checkpoint axis is promising for MM.
• Recent large-scale studies using checkpoint inhibitors have yielded disappointing results in MM.

Conclusions:

• The low mutational load in MM suggests limited benefit from single-agent immunotherapy.
• Combination approaches, including other immunotherapies, vaccines, or chemotherapy, are likely necessary to achieve durable survival benefits in MM.